ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

One of the most common treatments for obstructive sleep apnea is continuous positive airway pressure (CPAP) applied by ... but there are also bundles for ResMed AirSense 10 ($339), Fisher ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive ... ResMed's second-quarter revenue rose 10% to $1.28 billion, driven by increased demand for its ...

Q2 revenue rose 10.2% year over year ... devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining technological ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital ... and expand its market reach. ResMed's 10.2% revenue jump in Q2 was ...